GO:1903109 positive regulation of mitochondrial transcription

Mitochondria contain their own circular genome, and its expression depends on a dedicated transcription machinery that is entirely encoded by nuclear genes. GO:1903109, positive regulation of mitochondrial transcription, captures the regulatory inputs that increase the rate or extent of transcription from mitochondrial promoters. This process is central to mitochondrial biogenesis, because the mitochondrial DNA (mtDNA) encodes essential subunits of the oxidative phosphorylation (OXPHOS) complexes, and their abundance must match cellular energy demand. Researchers study GO:1903109 to understand how cells adapt to hypoxia, metabolic stress and immune activation, and to identify therapeutic targets in cardiomyopathy, renal disease and cancer. Mechanistically, positive regulation of mitochondrial transcription is achieved by increasing the activity or abundance of the mitochondrial RNA polymerase POLRMT and its associated transcription factors TFAM, TFB1M and TFB2M, or by relieving repression at the mitochondrial promoter. In immune cells, the transcription factor BHLHE40 programs mitochondrial regulation of resident CD8+ T cell fitness and functionality, illustrating how nuclear transcription factors can indirectly drive mitochondrial transcription programs. In the heart, the DYRK1B-STAT3 axis drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics, a phenotype that involves altered mitochondrial transcription factor expression. In renal epithelial cells, hypoxia modulates mitochondrial transcription factors, with implications for hypertensive renal physiology. Because mitochondrial transcription is a convergence point for metabolic, hypoxic and immune signals, it is a high-value target for functional genomics. Knockout and knock-in models of POLRMT, TFAM, TFB1M, TFB2M and upstream regulators such as BHLHE40, STAT3 and DYRK1B allow researchers to dissect cause and effect. Bioinformatics analyses of diabetic cardiomyopathy and diabetic retinopathy have further highlighted mitochondrial metabolic disorder and immune infiltration as processes linked to mitochondrial transcription regulators. This article summarizes the definition, mechanism, key genes, disease links and experimental methods for GO:1903109, with a focus on CRISPR-based models and screening.

GO:1903109, positive regulation of mitochondrial transcription, is a biological process term defined as any process that activates or increases the frequency, rate or extent of transcription occurring in the mitochondrion. It is a positive regulatory counterpart to negative regulation of mitochondrial transcription and is a child of regulation of mitochondrial transcription. The term covers activation of transcription from mitochondrial promoters, including upregulation of mitochondrial transcription and activation of mitochondrial transcription. It does not describe the basal transcription machinery itself, but rather the upstream and downstream events that elevate mitochondrial transcription above baseline.

Positive regulation of mitochondrial transcription is important because it sets the output of the mitochondrial genome, which encodes core subunits of the electron transport chain and is required for ATP production, reactive oxygen species signaling and metabolic adaptation. When this process is insufficient, cells cannot meet energy demand, contributing to cardiac hypertrophy, heart failure and diabetic cardiomyopathy. When it is dysregulated in cancer or immune cells, it can reprogram metabolism and promote tumor progression or alter T cell fitness. Therefore, understanding GO:1903109 provides mechanistic insight into metabolic disease, immune function and cancer, and offers targets for pharmacological or genetic intervention.

The following genes and proteins are central to positive regulation of mitochondrial transcription, based on their established roles in mitochondrial transcription, mitochondrial biogenesis and disease models.

Positive regulation of mitochondrial transcription is controlled at multiple levels. Upstream, nuclear transcription factors such as BHLHE40 and STAT3, together with kinases like DYRK1B, integrate immune, growth and stress signals to modulate mitochondrial gene expression programs. Hypoxia regulates mitochondrial transcription factors in renal epithelial cells, linking oxygen availability to mitochondrial transcription and hypertensive renal physiology. Coactivators such as PGC-1alpha coordinate nuclear and mitochondrial gene expression during mitochondrial biogenesis, and pharmacological approaches can enhance this program. In cancer, mitochondrial genome transfer and metabolic reprogramming can alter mitochondrial transcription in recipient cells, promoting TGFbeta1-mediated tumor progression. In diabetic retinopathy, macrophage polarisation and mitochondria-related biomarkers reflect immune-metabolic regulation of mitochondrial transcription. Together, these layers ensure that mitochondrial transcription is matched to cellular energy demand and stress conditions.

The DYRK1B-STAT3 axis drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics, a process that involves dysregulation of mitochondrial transcription and OXPHOS capacity. Positive regulation of mitochondrial transcription is therefore a potential compensatory or maladaptive node in heart disease, and targeting DYRK1B or STAT3 may restore mitochondrial function. Experimental models include cardiomyocyte-specific knockout of Dyrk1b or Stat3 and point-mutation of the DYRK1B kinase domain.

Bioinformatics analyses of diabetic cardiomyopathy have highlighted mitochondrial metabolic disorder and immune infiltration as key features, implicating mitochondrial transcription regulators in disease pathogenesis. In diabetic retinopathy, macrophage polarisation and mitochondria-related biomarkers have been identified, further linking mitochondrial transcription programs to immune-metabolic complications of diabetes. These findings support the use of mitochondrial transcription readouts as biomarkers and therapeutic targets in diabetic complications.

Hypoxia-mediated regulation of mitochondrial transcription factors in renal epithelial cells has implications for hypertensive renal physiology, suggesting that oxygen sensing and mitochondrial transcription are coupled in the kidney. Positive regulation of mitochondrial transcription may therefore influence renal sodium handling, oxidative stress and injury responses relevant to hypertension. Experimental models include renal epithelial cell lines under hypoxia and knockout of hypoxia-inducible factors.

Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells and promotes TGFbeta1-mediated tumor progression, demonstrating that mitochondrial transcription changes can be transmitted between cells. In CD8+ T cells, BHLHE40 programs mitochondrial regulation of resident T cell fitness and functionality, linking mitochondrial transcription to anti-tumor immunity. These studies position GO:1903109 as a node connecting mitochondrial metabolism, immune function and cancer.

RNA-seq can quantify mitochondrial DNA-encoded transcripts such as MT-CO1, MT-ND1 and MT-CYB, providing a direct readout of positive regulation of mitochondrial transcription. In diabetic cardiomyopathy and retinopathy studies, bioinformatics analyses of transcriptomic data have identified mitochondrial metabolic disorder and immune infiltration signatures. These methods are typically applied to cells or tissues with genetic or pharmacological perturbation of mitochondrial transcription regulators.

CRISPR knockout of POLRMT, TFAM, TFB1M, TFB2M or upstream regulators such as BHLHE40, STAT3 and DYRK1B allows causal testing of their role in mitochondrial transcription. Knock-in of point mutations or tags enables precise dissection of promoter binding, kinase activity or protein localization. These models are combined with mitochondrial transcription readouts and OXPHOS functional assays.

Proteomics of mitochondrial fractions can quantify POLRMT, TFAM, TFB1M, TFB2M, TEFM and OXPHOS subunits, revealing how positive regulation of mitochondrial transcription changes mitochondrial protein composition. Mitochondrial fractionation with markers such as TOMM20, SDHA and VDAC1 ensures purity and allows normalization. These approaches are useful in cardiac, renal and cancer models where mitochondrial bioenergetics is impaired.

Fluorescent tagging of TFAM or POLRMT enables live-cell imaging of mitochondrial nucleoids and transcription foci. Mitochondrial transcription reporter systems can measure promoter activity in response to hypoxia or metabolic stress. Imaging is often combined with CRISPR knock-in of tagged alleles to preserve endogenous regulation.

Researchers studying positive regulation of mitochondrial transcription-related genes often need to determine whether a candidate gene is causally involved in mitochondrial gene expression, or whether it is merely a correlative biomarker. This requires precise genetic models that can knock out, mutate, tag or overexpress the gene of interest in relevant cell types, combined with quantitative readouts of mitochondrial transcription and OXPHOS function. EDITGENE provides end-to-end CRISPR services to build these models and to screen for novel regulators of GO:1903109.

GO:1903109, positive regulation of mitochondrial transcription, is a central biological process that matches mitochondrial gene expression to cellular energy demand and stress. Its dysregulation is implicated in cardiac hypertrophy, heart failure, diabetic complications, hypertensive renal physiology and cancer, making it a high-value target for mechanistic and therapeutic research. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with RNA-seq, proteomics and imaging, provide the tools needed to dissect this process. EDITGENE supports researchers with end-to-end CRISPR services and bioinformatics to accelerate discovery in mitochondrial transcription biology.